JP2020529993A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529993A5 JP2020529993A5 JP2020505356A JP2020505356A JP2020529993A5 JP 2020529993 A5 JP2020529993 A5 JP 2020529993A5 JP 2020505356 A JP2020505356 A JP 2020505356A JP 2020505356 A JP2020505356 A JP 2020505356A JP 2020529993 A5 JP2020529993 A5 JP 2020529993A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- optionally substituted
- alkyl
- substituted
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 201000011510 cancer Diseases 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- -1 cyano, amino Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 150000003973 alkyl amines Chemical class 0.000 claims 4
- 150000001412 amines Chemical class 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000000649 small cell carcinoma Diseases 0.000 claims 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims 2
- 206010034299 Penile cancer Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 210000000941 bile Anatomy 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 230000001605 fetal effect Effects 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 210000000244 kidney pelvis Anatomy 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 125000006193 alkinyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 210000004252 chorionic villi Anatomy 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 0 CC(*(CC12CC1)Cc1c2ccc(C2**C2)c1)=O Chemical compound CC(*(CC12CC1)Cc1c2ccc(C2**C2)c1)=O 0.000 description 5
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539734P | 2017-08-01 | 2017-08-01 | |
| US62/539,734 | 2017-08-01 | ||
| PCT/US2018/044580 WO2019028008A1 (en) | 2017-08-01 | 2018-07-31 | 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020529993A JP2020529993A (ja) | 2020-10-15 |
| JP2020529993A5 true JP2020529993A5 (enExample) | 2021-09-09 |
| JP7203816B2 JP7203816B2 (ja) | 2023-01-13 |
Family
ID=65233095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505356A Active JP7203816B2 (ja) | 2017-08-01 | 2018-07-31 | １，２－ジヒドロ－３Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－３－オン類似体 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11124518B2 (enExample) |
| EP (1) | EP3661918B1 (enExample) |
| JP (1) | JP7203816B2 (enExample) |
| KR (1) | KR20200034781A (enExample) |
| CN (1) | CN111094253B (enExample) |
| AR (1) | AR112774A1 (enExample) |
| AU (1) | AU2018312448B2 (enExample) |
| BR (1) | BR112020002104A2 (enExample) |
| CA (1) | CA3071405A1 (enExample) |
| ES (1) | ES2980537T3 (enExample) |
| IL (1) | IL272262A (enExample) |
| MX (1) | MX2020001235A (enExample) |
| RU (1) | RU2020105058A (enExample) |
| SG (1) | SG11202000789WA (enExample) |
| TW (1) | TW201910335A (enExample) |
| WO (1) | WO2019028008A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3078945A1 (en) | 2017-10-09 | 2019-04-18 | Nuvation Bo Inc. | Heterocyclic compounds and uses thereof |
| EP3694861A4 (en) * | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| CA3088997A1 (en) * | 2018-02-28 | 2019-09-06 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of treating cancer using the same |
| BR112020018286A2 (pt) * | 2018-03-09 | 2020-12-29 | Recurium Ip Holdings, Llc | 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas |
| CN110872296B (zh) * | 2018-08-31 | 2023-05-23 | 上海弘翊生物科技有限公司 | 一种二氢异吲哚-1H-吡唑并[3,4-d]嘧啶酮化合物、其制备方法和应用 |
| JP2022526831A (ja) * | 2019-04-09 | 2022-05-26 | ニューベイション・バイオ・インコーポレイテッド | ヘテロ環式化合物およびその使用 |
| US20220169646A1 (en) * | 2019-04-09 | 2022-06-02 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| WO2020210380A1 (en) * | 2019-04-09 | 2020-10-15 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| WO2020210320A1 (en) * | 2019-04-11 | 2020-10-15 | Recurium Ip Holdings, Llc | Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| BR112021026618A2 (pt) | 2019-06-28 | 2022-06-07 | Shanghai Pharmaceuticals Holding Co Ltd | Composto de pirazolpirimidina, método de preparação do mesmo e aplicações do mesmo |
| CN112142748B (zh) * | 2019-06-28 | 2023-07-04 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| CN112442049A (zh) * | 2019-09-03 | 2021-03-05 | 微境生物医药科技(上海)有限公司 | 作为Wee1抑制剂的嘧啶衍生物 |
| WO2021097139A1 (en) | 2019-11-15 | 2021-05-20 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| CA3165472A1 (en) * | 2019-12-20 | 2021-06-24 | Recurium Ip Holdings, Llc | Combinations |
| CA3182270A1 (en) * | 2020-05-15 | 2021-11-18 | Recurium Ip Holdings, Llc | Mono- and combination therapies |
| AU2021290701A1 (en) | 2020-06-17 | 2023-02-02 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Pyrazolo(3,4-d)pyrimidine-3-ketone derivative as Wee-1 inhibitor |
| KR20230038523A (ko) | 2020-07-09 | 2023-03-20 | 리커리엄 아이피 홀딩스, 엘엘씨 | Wee1 억제제의 염 및 형태 |
| CN114805357B (zh) * | 2021-01-21 | 2023-12-19 | 四川大学 | 一种靶向setdb1-ttd的小分子抑制剂及其制药用途 |
| EP4332104A4 (en) * | 2021-04-30 | 2025-04-16 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Fused ring compound as a WEE-1 inhibitor, as well as production process and use thereof |
| US20240254123A1 (en) * | 2021-06-04 | 2024-08-01 | Aprea Therapeutics, Inc. | Pyridopyrimidine derivatives useful as wee1 kinase inhibitors |
| CN117751122B (zh) * | 2021-08-11 | 2026-07-24 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物 |
| WO2023045942A1 (zh) * | 2021-09-22 | 2023-03-30 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物 |
| WO2023166080A1 (en) | 2022-03-01 | 2023-09-07 | Step Pharma S.A.S. | Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor |
| WO2026112362A1 (en) * | 2024-11-21 | 2026-05-28 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5190271B2 (ja) | 2005-01-14 | 2013-04-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キナーゼ阻害剤としての５員の環付加複素環式ピリミジン |
| PE20080695A1 (es) * | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| EP2213673B1 (en) * | 2007-10-23 | 2013-06-05 | Msd K.K. | Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
| SMT201900344T1 (it) * | 2012-09-10 | 2019-07-11 | Principia Biopharma Inc | Composti di pirazolopirimidina come inibitori di chinasi |
| GB201612092D0 (en) * | 2016-07-12 | 2016-08-24 | Almac Discovery Ltd | Pharmaceutical compounds |
-
2018
- 2018-07-31 MX MX2020001235A patent/MX2020001235A/es unknown
- 2018-07-31 ES ES18842344T patent/ES2980537T3/es active Active
- 2018-07-31 AU AU2018312448A patent/AU2018312448B2/en not_active Ceased
- 2018-07-31 BR BR112020002104-0A patent/BR112020002104A2/pt not_active Application Discontinuation
- 2018-07-31 JP JP2020505356A patent/JP7203816B2/ja active Active
- 2018-07-31 US US16/635,348 patent/US11124518B2/en active Active
- 2018-07-31 KR KR1020207005636A patent/KR20200034781A/ko not_active Ceased
- 2018-07-31 TW TW107126578A patent/TW201910335A/zh unknown
- 2018-07-31 EP EP18842344.6A patent/EP3661918B1/en active Active
- 2018-07-31 CN CN201880059242.4A patent/CN111094253B/zh active Active
- 2018-07-31 CA CA3071405A patent/CA3071405A1/en active Pending
- 2018-07-31 RU RU2020105058A patent/RU2020105058A/ru unknown
- 2018-07-31 SG SG11202000789WA patent/SG11202000789WA/en unknown
- 2018-07-31 WO PCT/US2018/044580 patent/WO2019028008A1/en not_active Ceased
- 2018-08-01 AR ARP180102185A patent/AR112774A1/es not_active Application Discontinuation
-
2020
- 2020-01-26 IL IL272262A patent/IL272262A/en unknown
-
2021
- 2021-06-15 US US17/304,154 patent/US20210317124A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020105058A (ru) | Аналоги 1,2-дигидро-3н-пиразоло[3,4-d]пиримидин-3-она | |
| JP2020517616A5 (enExample) | ||
| JP2018516238A5 (enExample) | ||
| JP2017537080A5 (enExample) | ||
| RU2016108667A (ru) | Комбинированная терапия для лечения рака | |
| JP2016528246A5 (enExample) | ||
| FI4019019T3 (fi) | Rilutsolin, rilutsolin aihiolääkkeiden tai rilutsolin analogien käyttö immunoterapioiden kanssa syövän hoidossa | |
| JP2020514252A5 (enExample) | ||
| RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
| RU2017105781A (ru) | Индазольные соединения в качестве ингибиторов киназы fgfr, их получение и применение | |
| JP2016530283A5 (enExample) | ||
| RU2010128107A (ru) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp | |
| JP2017528502A5 (enExample) | ||
| RU2015121431A (ru) | Замещенные производные индол-5-ола и их терапевтическое применение | |
| JP2008528467A5 (enExample) | ||
| RU2014147105A (ru) | 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения | |
| JP2010538003A5 (enExample) | ||
| JP2017535614A5 (enExample) | ||
| JP2016501223A5 (enExample) | ||
| JP2020536971A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| RU2015121424A (ru) | Комбинированная терапия | |
| JP2011506402A5 (enExample) | ||
| AR080151A1 (es) | Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia | |
| RU2014101626A (ru) | Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты |